Seaport Therapeutics, Inc. (SPTX)

PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers

PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers

Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers

Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers

Seaport Therapeutics to Participate in Two Upcoming Investor Conferences

Seaport Therapeutics to Participate in Two Upcoming Investor Conferences

U.S. IPO Weekly Recap: Biotech, Early-Stage Mining, And Bill Ackman Close Out The April IPO Market

PureTech Health shares boosted as investee Seaport Therapeutics prices Nasdaq IPO

Seaport Therapeutics raises about $255 million in upsized IPO

Seaport Therapeutics Announces Pricing of Upsized Initial Public Offering

Drug developer Seaport Therapeutics targets $912 million valuation in US IPO